(4-{[6-ethyl-2'-propyl-4'-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl)biphenyl-3-ylamino]methyl}-2-hydroxymethylphenyl)methanol | 915004-33-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-{[6-ethyl-2'-propyl-4'-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl)biphenyl-3-ylamino]methyl}-2-hydroxymethylphenyl)methanol
• 英文别名: 2-[4-[5-[[3,4-Bis(hydroxymethyl)phenyl]methylamino]-2-ethylphenyl]-3-propylphenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol
• CAS: 915004-33-0
• 化学式: C₂₉H₃₁F₆NO₃
• 分子量: 555.56
• InChiKey: DABGHLZIGSNHFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Triaromatic vitamin D analogues
  申请人：——

  公开号：US20030195259A1

  公开（公告）日：2003-10-16

  The invention relates, as novel and useful industrial products, to triaromatic compounds, which are vitamin D analogues, of general formula (I): 1 and also to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

  该发明涉及一种新颖且有用的工业产品，即一般式(I)的三芳基化合物，它们是维生素D类似物，同时涉及一种制备它们的方法以及它们在用于人类或兽医药物的制剂中的使用，或者在化妆品制剂中的使用。
• Beta-lactamase inhibitor prodrug
  申请人：Marfat Anthony

  公开号：US20050004093A1

  公开（公告）日：2005-01-06

  Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, each X is methylene, and Y is O, or wherein R is H, each X is O and Y is methylene, and solvates thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention, or a solvate thereof, an optional beta-lactam antibiotic and at least one pharmaceutically acceptable carrier. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.

  本发明揭示了6-β-羟甲基青霉烷酸磺酸酯的前药物，其结构为：其中R为氢或甲基，每个X为亚甲基，Y为氧，或其中R为氢，每个X为氧，Y为亚甲基，以及其溶剂化物。还揭示了包含本发明的前药物或其溶剂化物、可选的β-内酰胺类抗生素和至少一种药学上可接受的载体的制药组合物。此外，还揭示了通过给哺乳动物注射有效量的β-内酰胺类抗生素和本发明的前药物或其溶剂化物的增效剂量来提高β-内酰胺类抗生素的治疗效果的方法。此外，还揭示了通过给需要治疗细菌感染的哺乳动物注射本发明的制药组合物的治疗有效量来治疗细菌感染的方法。
• Pharmaceutical compositions comprising organopolysiloxane elastomers and solubilized bioactive compounds
  申请人：Barthez Nathalie

  公开号：US20080194528A1

  公开（公告）日：2008-08-14

  Stable, anhydrous pharmaceutical compositions contain an organopolysiloxane elastomer and, as bioactive ingredient, at least one vitamin D compound in a solubilized form, and are useful for the topical treatment of psoriasis and other skin disorders/afflictions.
• US6924400B2
  申请人：——

  公开号：US6924400B2

  公开（公告）日：2005-08-02